{"url_path":"/sec/plrx/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1746473/0001746473-26-000115-index.html","accession_number":"0001746473-26-000115","cik":"0001746473","ticker":"PLRX","issuer_name":"PLIANT THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1746473/0001746473-26-000115-index.html","primary_entity_key":"0001746473","primary_entity_name":"PLIANT THERAPEUTICS, INC."},"word_count":79,"has_tables":true,"body_markdown":"Item 9.01     Financial Statements and Exhibits.\n\n(d) Exhibits. \n\nExhibit\n\nNo.\nDescription\n\n[99.1](plrx-2026811xexx991.htm)\n\n[Press Release issued by the Company dated](plrx-2026811xexx991.htm)[August](plrx-2026811xexx991.htm)[11](plrx-2026811xexx991.htm)[, 2026](plrx-2026811xexx991.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nPLIANT THERAPEUTICS, INC.\n\nDate: August 11, 2026\nBy:/s/ Keith Cummings\n\nKeith Cummings, M.D., MBA\n\nChief Financial Officer"}